Ultragenyx Pharmaceutical (RARE) P/E Ratio
P/E Ratio as of Jul 1, 2025: -6.17
Average-6.30
Median-6.31
Minimum-6.68
Maximum-6.15
-6.17
Past Month-0.38 (6.56%)
The P/E ratio for Ultragenyx Pharmaceutical (RARE) is -6.17 as of Jul 1, 2025. This represents a decrease of -6.52% compared to its 12-month average P/E ratio of -6.6. A higher P/E ratio suggests that investors expect strong future earnings growth, while a lower P/E ratio may indicate a potentially undervalued stock or slowing growth.
Ultragenyx Pharmaceutical P/E Ratio Formula = Stock Price ÷ Earnings Per Share (EPS)
Ultragenyx Pharmaceutical’s P/E ratio represents the valuation of the company based on its earnings. It’s calculated by dividing the company’s latest stock price by its diluted earnings per share (EPS) over the past 12 months. The P/E ratio helps investors assess how much they are paying for each dollar of earnings, offering valuable insights when comparing Ultragenyx Pharmaceutical to industry peers.
Ultragenyx Pharmaceutical P/E Ratio Formula = Stock Price ÷ Earnings Per Share (EPS)
Ultragenyx Pharmaceutical’s P/E ratio represents the valuation of the company based on its earnings. It’s calculated by dividing the company’s latest stock price by its diluted earnings per share (EPS) over the past 12 months. The P/E ratio helps investors assess how much they are paying for each dollar of earnings, offering valuable insights when comparing Ultragenyx Pharmaceutical to industry peers.
Ultragenyx Pharmaceutical (RARE) P/E Ratio Insights
See Ultragenyx Pharmaceutical’s latest P/E ratio, historical trends, and valuation insights with AI-powered fundamental data and custom analysis.
Start investing in Ultragenyx Pharmaceutical (RARE)
Order type
Buy in
Order amount
Est. shares
0 shares
Ultragenyx Pharmaceutical (RARE) P/E Ratio Historic Data
| Date | Stock price | P/E ratio |
|---|---|---|
| Jul 1, 2025 | $36.26 | -6.17 |
| Jun 2, 2025 | $36.14 | -6.15 |
| May 1, 2025 | $38.97 | -6.15 |
| Apr 1, 2025 | $33.84 | -5.34 |
| Mar 3, 2025 | $41.26 | -6.51 |
| Feb 3, 2025 | $43.42 | -6.72 |
| Jan 2, 2025 | $41.15 | -6.37 |
Ultragenyx Pharmaceutical (RARE) End of Year P/E Ratio
| Date | P/E ratio | Change |
|---|---|---|
| 2025 | -6.17 | -5.22% |
| 2024 | -6.51 | +22.14% |
| 2023 | -5.33 | +11.97% |
| 2022 | -4.76 | -62.07% |
| 2021 | -12.55 | -71.50% |
| 2020 | -44.03 | — |
FAQs About Ultragenyx Pharmaceutical (RARE) P/E ratio
The latest P/E ratio of Ultragenyx Pharmaceutical (RARE) is -6.17, as of Jul 1, 2025. This is calculated based on its current stock price and earnings per share (EPS).
Ultragenyx Pharmaceutical’s last 12-month average P/E ratio is -6.6, compared to its current P/E ratio of -6.17. This reflects a decrease of -6.52%.
Ultragenyx Pharmaceutical’s current P/E ratio of -6.17 is lower than its last 12-month average P/E of -6.6. A higher P/E can indicate strong future growth expectations, while a lower P/E might suggest undervaluation.
Ultragenyx Pharmaceutical’s average P/E ratio over the last 3 years is -5.45. Comparing this to the current P/E helps assess recent valuation trends and whether the stock is trading above or below its mid-term historical range.
Ultragenyx Pharmaceutical’s average P/E ratio over the last 5 years is -11.71. A deviation from this historical average may indicate shifts in growth expectations, profitability, or broader market conditions affecting valuation.